The paradox of cytokine monitoring - Predictor of immunologic activity as well as immunologic silence following cardiac transplantation

Transplantation

Volumn 61, Issue 6, 1996, Pages 909-915

  Kimball, Pamela M ^a,b   Radovancěvíc, Brano ^b   Isom, Trissy ^b   Spickard, Angie ^a   Frazier, O H ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEXAS HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8;

ARTICLE; BIOLOGICAL MONITORING; CLINICAL ARTICLE; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; PRIORITY JOURNAL;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CYTOKINES; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; INTERLEUKIN-6; INTERLEUKIN-8; MONITORING, IMMUNOLOGIC; MUROMONAB-CD3; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0029871431     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199603270-00012     Document Type: Article

References (30)

1. Lower RR, Stofer N, Shumway N. Transplantation of the heart. J Thorac Cardiovasc Surg 1991; 41: 196.
2. Sheldon S, Hasleton P, Yonan N, et at. Rejection in heart transplantation strongly correlates with HLA-DR antigen mismatch. Transplantation 1994; 58: 719.
3. Kerman R, Kimball P, Scheinen S, Radovancěvíc B, Van Buren C, Kahan B, Frazier H. The relationship among donor-recipient HLA mismatches, rejection and death from coronary artery disease in cardiac transplant recipients. Transplantation 1994; 57: 88.
4. Tilg H, Nordberg J, Vogel W, et al. Circulating levels of interleukin 6 and C-reactive protein after liver transplantation. Transplantation 1992; 54: 142.
5. Simpson M, Madras P, Cornaby A, et al. Sequential determinations of urinary cytology and plasma and urinary lymphokines in the management of renal allograft recipients. Transplantation 1989; 47: 218.
6. Tilg H, Ceska M, Vogel W, Herold M, Margreiter R, Huber C. Interleukin 8 serum concentrations after liver transplantation. Transplantation 1992; 53: 800.
7. Dallman M, Montgomery R, Larsen C, Wanders A, Wells A. Cytokine gene expression: analysis using northen blotting, polymerase chain reaction and in situ hybridization. Immunol Rev 1991; 119: 163.
8. Yoshimura N, Oka T, Kahan B. Sequential determinations of serum interleukine 6 levels as an immunodiagnostic tool to differentiate rejection from nephrotoxicity in renal allograft recipients. Transplantation 1991; 51: 172.
9. Kimball P, Radovancěvíc B, Isom T, Frazier B, Kerman R. Cytokine panel predicts early rejection and therapeutic response after cardiac transplantation. Transplant Proc 1995; 27: 1286.
10. Schwartz M, Belland S, Mull R, Kussmaul W, Tomszewski J, Eisen H. Peripheral blood and coronary sinus cytokine levels cannot detect significant rejection in cardiac transplant patients. JACC 1992; 19: 83.
11. Thavasu P, Longhurst S, Slevin M, Balkwill. Measuring cytokine levels in blood: importance of anticoagulants, processing and storage conditions. J Immunol Methods 1992; 153: 115.
12. Riches P, Gooding R, Millar B, Rowbottom A. Influence of collection and separation of blood samples on plasma IL-1, IL-6, and TNFa concentrations. J Immunol Methods 1992; 153: 125.
13. Baigrie R, Lamont P, Dallman M, Morris P. The release of IL-1 precedes that of IL-6 in patients undergoing major surgery. Lymphokine Cytokine Res 1991; 10: 253.
14. Muragato A, Ogawa M, Yasuda T, et al. Serum interleukine 6, C-reactive protein and pancreatic secretory trypsin inhibitor as acute phase reactants after major thoraco-abdominal surgery. Immunol Invest 1990; 19: 271.
15. Halloran P, Cockfield S, Madrenas J. The mediators of inflammation(IL-1, interferon-tau, and tumor necrosis factor) and their relevance to rejection. Transplant Proc 1989; 21: 26.
16. Kutukculer N, Clark K, Rigg K, et al. The value of posttransplant monitoring of IL-2, IL-3, IL-4, IL-6, IL-8 and soluble CD23 in the plasma of renal allograft recipients. Transplantation 1995; 59: 333.
17. Duncan J, Radovancěvíc B, Frazier O. Ventricular assist devices. Cardiac Surgery: state of the art reviews. 1990; 4: 321.
18. Radovancěvíc B, Biroluljew S, Frazier O. Treating cardiac allograft rejection: present approach and analysis of 100 consecutive patients. J Heart Transplant 1990; 9: 288.
19. McAllister H, Schnee M, Radovancěvíc B, et al. A system for grading cardiac allograft rejection. Texas Heart Inst J 1986; 13: 1.
20. Van Oers M, Van der Heyden A, Aarden L. Interleukin 6 in serum and urine of renal transplant recipients. Clin Exp Immunol 1988; 71: 314.
21. Saito R, Prehn J, Xiao-Jing Z, et al. The participation of tumor necrosis factor in the pathogenesis of lung allograft rejection in the rat. Transplantation 1993; 55: 967.
22. Young J, Windsor N, Smart F, et al. Inability of isolated soluble interleukin 2 receptor levels to predict biopsy rejection scores after heart transplantation. Transplantation 1991; 51: 636.
23. Roodman S, Miller L, Cheng T. Role of interleukin 2 receptors in immunologic monitoring following cardiac transplantation. Transplantation 1988; 45: 1050.
24. Noronha I, Daniel V, Rambausek M, Waldherr R, Opelz G. Soluble interleukin 2 receptor and tumor necrosis factor plasma levels in renal allograft recipients. Transplant Proc 1990; 22: 1859.
25. Kirk A, Bollinger R, Finn O. Rapid comprehensive analysis of human cytokine mRNA and its application to the study of acute renal allograft rejection. Hum Immunol 1995; 43: 113.
26. Imada M, Estelle F, Simons R, Jay F, HayGlass K. Antigen mediated and polyclonal stimulation of human cytokine production elicit qualitatively different patterns of cytokine gene expression. Int Immunol 1995; 7: 229.
27. Jeyarajah D, Kadakia R, O'Toole K, et al. Changes in urinary cytokine mRNA profile after successful therapy for acute celllular renal allograft rejection. Transplant Proc 1995; 27: 887.
28. Fealy M, Most D, Huie P, et al. Association of down regulation of cytokine activity with rat hind limb allograft survival. Transplant 1995; 59: 1475.
29. Larsen C, Anderson A, Appella E, Oppenheim J, Matsushima K. The neutrophil activating protein (NAP-1) is also chemotactic for T lymphocytes. Science 1989; 243: 1464.
30. Modi W, Dean M, Sevanex H, Mukaida N, Matsushima K, O'Brien S. Monocyte derived neutrophil chemotactic factor (MDNCF/IL-8) resides in a gene cluster along with several other members of the platelet factor 4 gene superfamily. Hum Genet 1990; 84: 185.